ORAGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was 0.00 shares.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 200.00K shares.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-06-30 was 0.00 shares.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-03-31 was 0.00 shares.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 756.54K shares.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2013 was 31.53K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2021-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-29 | 756.54K shares 10-K/A · filed 2022-07-29 |
| 2021-09-30 | 200.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | |
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-15 | |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | |
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-15 | |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-16 | |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | |
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | |
| 2015-03-31 | 0.00 shares 10-Q · filed 2015-05-08 | |
| 2014-03-31 | 0.00 shares 10-Q · filed 2014-05-09 | |
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | 31.53K shares 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |